At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 50 enrolled
Drug / intervention
Oxcarbazepinedrug
Likely dose
Oxcarbazepine 600mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Oxcarbazepine on Serum Brain Derived Neurotrophic Factor (BDNF) in Bipolar Disorder
All India Institute of Medical Sciences, Bhubaneswar·interventional·Posted May 29, 2015·Updated May 7, 2019
In Brief
A Phase 4 clinical trial evaluating Oxcarbazepine for Bipolar Disorder. Completed, enrolled 50 participants across 1 site.
Detailed Summary
The present study has been designed to evaluate the change in serum BDNF level with oxcarbazepine monotherapy in bipolar disorder and to explore the possibility of its neuroprotective effect.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBipolar Disorder
CountriesIndia
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartJun 2015
Primary CompletionDec 2015
TodayJul 2026
First PostedMay 29, 2015
Enrollment StartJun 1, 2015
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 11.1 years ago
Interventions
Oxcarbazepinedrug
After baseline assessments, patients in test group will be prescribed Tab. Oxcarbazepine (600mg/daily in two divided dose for 1 week followed by 900mg/daily in two divided dose for next 3 weeks).